Marrow Therapeutics announced $173 million in combined funding:
a $53 million Series A co-led by Scion Life Sciences and venBio, followed by a $120 million Series B led by OrbiMed.
The funding will advance MAR-101, a preclinical candidate for sickle cell disease and beta thalassemia. It links an antibody that targets transferrin receptors to an siRNA payload intended to reduce BCL11A in bone-marrow cells, potentially restoring fetal hemoglobin production.
Marrow hopes an injected treatment could avoid some burdens of current gene therapies, which can require stem-cell collection, chemotherapy conditioning and transplantation. The comparison with one-time CRISPR therapy is a development goal—not evidence that MAR-101 is as effective or durable.
MAR-101 is still in IND-enabling studies; the company has not disclosed a clinical-trial start date. It has not yet shown human safety or efficacy, so the approach remains unproven.
Sources:
Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data
Marrow raises $173 million to develop blood disorder drugs
Marrow launches with $173M, with OrbiMed leading the $120M Series B
Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell
Marrow sets out to challenge genetic medicines for severe blood diseases
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
Marrow extracts $120M series B for blood disease drug
Marrow Unveils MAR-101, a Potential Gene Therapy Alternative for Sickle Cell Disease
Marrow Therapeutics Launches With $173 Million for Bone Marrow-Targeted Oligonucleotide Conjugates
Marrow Therapeutics Unveils $173M for 'Trojan Horse' Delivery of Blood ...
Marrow Therapeutics $173M Series B Funding (2026) | Investors & Contacts | Fundup AI
Marrow raised $173M for an siRNA drug it hopes can compete with a one- ...